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Endovascular revascularization of renal artery
stenosis in the solitary functioning kidney
Mark G. Davies, MD, PhD, MBA, Wael E. Saad, MD, Jean X. Bismuth, MD, Joseph J. Naoum, MD,
Eric K. Peden, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: Endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is considered effective.
This study evaluates the factors that impact long term anatomic and functional outcomes of endovascular therapy of
ARAS in patients with a solitary functioning kidney.
Methods: We performed a retrospective analysis of records from patients who underwent endovascular intervention for
ARAS and identified patients with a solitary functioning kidney (absent or nonfunctioning contralateral kidney) and
patients with contralateral normal kidney (for comparison) between January 1990 and January 2008. Indications for
intervention in the solitary functioning kidney were poorly controlled hypertension (diastolic blood pressure [BP] >90
mmHg on >3 antihypertensive medications) and/or elevated creatinine (Cr >1.5 mg/dL). Clinical benefit was defined
as freedom from composite recurrent symptoms (recurrent hypertension or renal-related morbidity-increase in persistent
creatinine >20% of baseline, progression to hemodialysis, and death from renal-related causes), anatomic patency and
patient survival were measured.
Results: A total of 242 patients (56% male, average age 69 years, range, 45-90) underwent angioplasty (23%) or
primary stenting (77%) of a single renal artery with a normal contralateral renal vessel and kidney and 73 patients
(58% male, average age 70 years, range, 52-89) underwent angioplasty (37%) or primary stenting (63%) for a solitary
functioning kidney. There were no significant differences in mortality or morbidity between the groups. There was
a significant difference in the long-term survival with 55  8% patients with a normal contralateral kidney vs 27 
7% patients with a solitary functioning kidney alive at 10 years. Clinical benefit was 67  6% and 67  4% at 5 years
and 63  8% and 62  4% at 10 years for solitary functioning kidney and normal contralateral groups, respectively.
Using proportional hazard analysis, the predictors of long-term clinical benefit were ipsilateral kidney size (>9 cm),
no immediate deterioration in function, and an estimated Glomerular Filtration Rate (eGFR) >30 mL/min/1.73m2.
Neither control of diabetes nor the administration of statins was shown to influence outcomes in the solitary functioning
kidney.
Conclusion: Intervention in patients with a solitary functioning kidney is a safe procedure and improves or stabilizes renal
function in 82% of patients. Clinical benefit is dictated by preoperative GFR, renal size, and the occurrence of acute
functional injury after the procedure. (J Vasc Surg 2009;49:953-60.)While controversy remains on the endovascular therapy
for symptomatic atherosclerotic renal artery stenosis (ARAS),
it is considered effective and appears to have significant
benefits in the well-selected patient.1-7 Acute functional
injury associated with renal intervention for atherosclerotic
disease is now recognized as an important clinical problem
and has led to a growing realization that embolic protection
devices may be required to protect the renal parenchyma
during renal interventions.8-10 We have recently shown
that acute functional renal injury occurs in approximately
20% of patients undergoing percutaneous renal artery in-
tervention, is more likely in the presence of an unrepaired
abdominal aortic aneurysm (AAA), diabetes, with pre-
existing renal disease, is a negative predictor of survival, is
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and death.11 We did find that the status of the contralateral
renal artery was important. Additionally, the advent of renal
embolic devices and the proposed indication of interven-
tion for use in atherosclerotic disease in a solitary kidney to
prevent functional injury added impetus for us to address
the outcomes of intervention in patients with a solitary
kidney. Thus, this study evaluates the factors that impact
long term anatomic and functional outcomes of endovas-
cular therapy of ARAS in patients with a solitary function-
ing kidney.
METHODS
Study design. We performed a retrospective analysis
of records from patients who underwent endovascular in-
tervention for ARAS and identified patients with a solitary
functioning kidney (definition: absent or nonfunctioning
contralateral kidney) and patients with a contralateral nor-
mal kidney between January 1990 and January 2008. Pa-
tients with bilateral ARAS were excluded from the study.
Indications for intervention were poorly controlled hyper-
tension (diastolic blood pressure [BP]90 mmHg on3
antihypertensive medications) and/or with elevated creat-
inine (1.5 mg/dL). For each patient, demographics,
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sclerosis were identified. We evaluated the early and late
outcomes of endovascular renal interventions in 73 patients
with solitary kidneys and compared them with results of
169 patients with normal contralateral kidneys who under-
went renal interventions during the same period.
Treatment algorithm. Patients with hypertension
and/or elevated serum creatinine levels had a diagnostic
study to identify the presence of renal artery stenosis. This
study consisted of standard angiography, magnetic reso-
nance angiography, renal isotope scan, or duplex ultra-
sound scan. Duplex ultrasound scan criteria to identify
renal artery stenosis have been previously described.12 In
the presence of clinical criteria defined by Rundback et al13
and a 60% stenosis on ultrasound scan or 50% stenosis
on magnetic resonance angiography/computerized tomo-
graphic angiography or a positive renal isotope scan, an-
giography was performed. Interventions were performed in
patients with renal artery stenosis 50% by angiography
regardless of comorbidities. The majority of these interven-
tions were transfemoral and no distal protection devices
were used. Patients not categorized into the clinical
criteria referenced were managed medically. Occluded
renal arteries and nonfunctioning kidneys were not
treated. Patients with creatinine 1.5 mg/mL were
hydrated overnight with normal saline and in the last 5
years received Mucomyst (Acetylcysteine, Bristol-Myers
Squibb Company, Princeton, NJ) 600 mg twice a day
(BID) prescribed orally (PO) 24 hours preoperatively
and 48 hours postoperatively. Patients were followed at
6-month intervals after the procedure. Blood pressure,
serum creatinine, and the number of antihypertensive
medications were identified during these intervals. Each
patient had at least one duplex ultrasound scan within 6
months of the procedure and an ultrasound scan every 6
months thereafter to assess patency. If the duplex ultra-
sound scan showed 60% stenosis and the patient had
recurrent symptoms, angiography was performed and re-
stenosis was treated if the arterial diameter was 50%.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Cerebrovascular disease included a history of stroke,
transient ischemic attack, or carotid artery revascularization.
Hypercholesterolemia was defined as fasting cholesterol
200 mg/dL. Diabetes was defined as a fasting plasma
glucose 110 mg/dL or an HbA1c 7%. Diabetics were
characterized as insulin dependent diabetes mellitus
(IDDM) or non-insulin dependent diabetes mellitus
(NIDDM). Hypertension was defined as diastolic BP
greater than 90 mm Hg on 3 antihypertensive medica-
tions. Metabolic syndrome was defined as previously de-
scribed14 (insulin resistance or impaired glucose tolerance,
hypertension, dyslipidemia, and abdominal obesity), with
the exception of abdominal circumference, which was not
routinely recorded. We substituted a body mass index score
30.0 as a positive score instead of an abdominal circum-
ference 102 cm or 88 cm for male or female patients,respectively. An elevated creatinine was defined as 1.5
mg/dL on two consecutive values during a 3-month pe-
riod. Chronic renal insufficiency was defined as a persistent
serum creatinine 1.5 mg/dL for greater than 6 months.
Estimated glomerular filtration rate (eGFR) was defined as
186.3 * serum creatinine1.154 * age0.203 * 0.742 (if
female) *1.212 (if African American). The baseline serum
creatinine was the value recorded closest to the procedure.
Patients were considered to have a “nonfunctioning kid-
ney” if any two of the following local criteria used at our
institution over the time of the study weremet: (1) a duplex
ultrasound scan identified a pole-to-pole length of less than
9 cm with no renal flow in the main renal artery and
parenchymal peak systolic velocity 10 cm/second; (2)
surgically or congenitally absent kidney; (3) no visible
nephrogram on contrast arteriogram. A normal contralat-
eral kidney was considered a kidney without evidence of
50% renal artery stenosis and not fulfilling criteria for a
“nonfunctioning kidney”. Renal Resistive Index was de-
fined from duplex scan imaging as 1-end-diastolic velocity/
peak systolic velocity (1-EDV/PSV)*100. Nephrosclerosis
was defined as grade 1: normal intrarenal vessels, orderly
progression of branching patterns (no pruning), normal
nephrogramwith distinct corticomedullary junction; grade 2:
ectasia of arcuate and distal interlobular arteries, peripheral
pruning, reduced arterial volume with normal renal mass,
normal nephrogram; grade 3: marked ectasia extending
centrally, total pruning with abrupt interlobar artery termi-
nations, marked reduced arterial volume with decreased
renal mass, and faint absent nephrogram. An endoluminal
procedural success was a residual stenosis of30%; failures
were residual stenosis 30%, by angiographic measure-
ment, including lesions unable to be dilated or crossed, and
occlusion within 30 days. A death within 30 days of the
procedure was considered procedure-related. Acute func-
tional renal injury was defined as a persistent increase in the
serum creatinine of 0.5 mg/dL at 1 month after the
procedure. Acute anatomic renal injury was defined as renal
artery dissection, perforation, acute occlusion, renal paren-
chymal infarction, and renal parenchymal perforation. Ac-
cess site complication was defined as hematoma, pseudoa-
neurysms, arteriovenous fistula, or a vessel injury requiring
either percutaneous or open intervention. Systemic com-
plications were any new cardiac pulmonary infectious or
non-renal systemic complication that required intervention or
halted discharge within 24 hours of the procedure. Response
in the hypertensive patient was defined as follows: “cured”
patients were normotensive (diastolic BP 90 mm Hg and
systolic BP140mmHg) without medications; “improved”
patients were normotensive (diastolic BP 90 mm Hg
and/or systolic BP 140 mm Hg) on the same (or re-
duced) number of medications, or had a diastolic BP 15
mm Hg below baseline with the same or reduced number
of medications. “No effect” patients had no change or
inability to meet these criteria for cure or improvement and
were considered a treatment failure. Early renal function
responses to angioplasty were defined as follows: “cured”
renal function required a serum creatinine concentration
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20% reduction in the serum creatinine concentration;
“stable” renal function required a20% increase or reduc-
tion in the serum creatinine concentration; “deterioration”
in renal function required a 20% increase in the serum
creatinine concentration.13 Stable renal function and dete-
rioration were considered treatment failures. Freedom
from renal-related morbidity was defined as a persistent
increase in creatinine 20% of baseline, progression to
hemodialysis, and death from renal-related causes.13
Statistical analysis. We performed our analysis on an
“intention-to-treat” basis. Measured values are reported as
percentages ormeans1 standarddeviation.Mann-Whitney
tests were used to test the difference between means. Fis-
cher’s or 2 tests were performed to test the significance
between proportions in each group. Survival and clinical
benefit rates are calculated using life table analysis and
reported using the Society for Vascular Surgery (SVS)
criteria. Standard errors are reported in actuarial analyses.
The log rank test was used to determine differences be-
tween life tables. Analyses were performed using JMP soft-
ware version 7.0 (SAS Institute, Cary, NC). Cox propor-
tional hazards models were employed for time-dependent
outcomes by preprocedural variables and periprocedural
variables.
RESULTS
Patient population. Over the time period, 242 pa-
tients (56% male, average age 69 years, range, 45-90)
underwent angioplasty (23%) or primary stenting (77%) of
a single renal artery with a normal contralateral renal vessel
and kidney, and 73 patients (58% male, average age 70
years, range, 52-89) underwent angioplasty (37%) or pri-
mary stenting (63%) for a solitary functioning kidney. One
hundred thirty-two patients with bilateral ARAS were ex-
cluded from the analysis. Hypertension was a much more
common presentation in the normal group compared to
the solitary functioning group where presentation with
renal insufficiency predominated (Table I). There was no
significant difference in the majority of the co-morbidities
between the two groups except that there were significantly
more patients with congestive heart failure and a history of
cerebrovascular disease in the solitary functioning kidney
group (Table I). When the status of renal insufficiency is
specifically examined, there was no significant difference in
the mean serum creatinine concentration and eGFR be-
tween the groups. However, the distribution of patients
with an eGFR 30 mL/min/1.73m2 was significantly
greater in the group with a solitary functioning kidney
(Table II). The intrinsic measures of the treated kidney (size,
resistive index, and nephrosclerosis grade) were equivalent in
both groups (Table II). The range of kidney size in the solitary
group was 13.7 to 7.0 cm pole-to-pole length.
Immediate outcomes (<3 months). Of the 242
planned interventions for a single renal artery with a normal
contralateral renal vessel, there was a 5% technical failure
rate (30% residual stenosis) but no periprocedural or
90-day mortalities. The procedure-related complicationrate for this group was 9% (all minor). Of the 73 planned
interventions for solitary functioning kidney, there was a 4%
technical failure rate (30% residual stenosis). There were
no periprocedural or 90-day mortalities. The procedure-
related complication rate (access and anatomic related) was
12% (all minor). There were no significant differences
between the two groups. The nature of the renal interven-
tions and categories of complications in both groups are
shown in Table III. Immediate renal clinical benefit was
superior in the solitary kidney group compared to the
normal contralateral group (Table IV). In the presence of a
normal contralateral kidney, only 6% of patients treated
demonstrated immediate clinical benefit of improved or
cured renal dysfunction and 86% showed no change within
3 months of procedure. In comparison, in the presence of a
solitary functioning kidney, 12% of patients treated dem-
onstrated immediate clinical benefit of improved or cured
renal dysfunction and 69% showed no change within 3
months of procedure (Table IV). However, there was a
significant difference in acute functional injury in the soli-
tary functioning kidney group (Table III) which was trans-
lated into a greater number of patients who were consid-
ered to have had a deterioration in their renal function at 3
months (Table IV). A preprocedure eGFR30 mL/min/
1.73m2 was associated with immediate clinical benefit in
those patients with a solitary kidney (relative risk [RR]
0.66, 95% confidence interval [CI] 0.45 to 0.95, P 
.0094). With respect to hypertension, there was a signifi-
cant clinical benefit in 60% of the normal contralateral
kidney group and 20% of the solitary functioning kidney
group (Table IV). The differences in the respective clinical
benefits achieved likely reflect the differences in presenting
symptoms between the groups.
Outcomes (>3 months). There was a significant dif-
Table I. Patients’ characteristics, presenting symptoms,
and co-morbidities
Normal Solitary P value
Demographics
Patients 242 73 —
Kidneys treated 242 73 —
Male 56% 58% .88
Average age (mean  SD,
years) 69  11 70  9 .47
Symptoms
Hypertension 70% 38% .001
Elevated creatinine 12% 21%
Hypertension with
elevated creatinine 18% 41%
Co-morbidities
Smoking history 60% 64% .56
Coronary artery disease 46% 53% .32
Congestive heart failure 24% 44% .003
Diabetes mellitus 28% 23% .41
Hyperlipidemia 65% 67% .77
Metabolic syndrome 70% 74% .52
Cerebrovascular 23% 33% .12
SD, Standard deviation.ference in the long-term survival between the normal con-
JOURNAL OF VASCULAR SURGERY
April 2009956 Davies et altralateral kidney and solitary functioning kidney groups
with patients with a solitary functioning kidney having a
lower life expectancy (Fig, A). In patients with a normal
contralateral kidney, survival was 76  4% and 55  8% at
5 and 10 years, while in patients with a solitary functioning
kidney survival was 62 6% and 27 7% at 5 and 10 years.
Table II. Kidney disease, creatinine levels, estimated
GFR, ipsilateral and contralateral hemodynamic, and
anatomy parameters
Normal Solitary P value
Kidney disease stage
1 8% 0% .05
2 27% 12% .05
3 51% 53% .1
4 11% 29% .05
5 3% 5% .09
Functional parameters
Creatinine (mg/dL) 1.5  1.0 1.9  1.0 .5
Mean eGFR mL/
min/1.73m2 55  24 40  18 .5
eGFR 30mL/
min/1.73m2 13% 35% .05
eGFR 30-60mL/
min/1.73m2 51% 53% .1
eGFR 60mL/
min/1.73m2 36% 12% .05
Ipsilateral kidney
anatomy
Kidney size 10.1  0.1 11.0  1.5 .1
Resistive index 0.73  0.1 0.75  0.11 .2
Nephrosclerosis 1.30  0.47 1.42  0.02 .3
Contralateral kidney
anatomy
Normal 100% 0% —
Stenosis (60%) 0% 0% —
Nonfunctioning 0% 23% —
Surgically absent 0% 15% —
Atrophy 0% 21% —
Occlusion 0% 42% —
Contralateral kidney
parameters
Kidney size 10.2  1.1 7.4  1.4 .05
Resistive index 0.73  0.09 — —
Nephrosclerosis 1.23  0.42 2.67  0.70 .01
eGFR, Estimated glomerular filtration rate.
Table III. Interventions and periprocedural
complications
Normal Solitary P value
Interventions
Angioplasty 23% 27% .51
Stent placement 77% 73% —
Predilation 45% 44% .88
Contralateral intervention 0% 0% —
Complications
Acute functional injury 14% 30% .006
Anatomic injury 4% 4% 1.0
Access site 5% 8% .38
Systemic 0% 0% —The eGFR 30 (hazard ratio [HR] 8.18, 2.61-20.4;95%CI; P .03), dialysis dependency (HR 4.1, 1.92-8.65;
P .003) and smoking (HR 2.5, 1.15-5.38; P .02) were
associated with decreased survival in the solitary function-
ing kidney group. Cumulative patency rates determined by
serial duplex scan imaging were 81  5% vs 87  6% at 5
years and 68% vs 83% at 10 years for normal contralateral
and solitary functioning kidney groups respectively (Fig, B).
By Cox proportional hazard analysis, hyperlipidemia
(HR 5.16, 1.40-20.1, P  .012) and metabolic syn-
drome (HR 3.62, 1.74-7.43, P  .014) were associated
with decreased patency. Restenosis rates were equivalent
at 5 years (85  4% vs 87  6%, normal contralateral vs
solitary functioning) and 10 years (78 9% vs 84 10%,
normal contralateral vs solitary functioning) (Fig, C).
Hyperlipidemia (HR 10.4, 2.1-64.7, P  .003) and an
elevated fasting blood sugar (HR 7.3, 1.9-30.8, P 
.004) were associated with increased rate of restenosis in
solitary functioning kidneys. Freedom from renal-related
morbidity (persistent increase in creatinine 20% of
baseline, progression to hemodialysis, and death from
renal-related causes) was 59  10% and 73  7% at 5
years for solitary functioning kidney and normal con-
tralateral groups, respectively (Fig, D). Recurrent symp-
toms and restenosis were highly correlated. Clinical ben-
efit from hypertension (84 9% at 10 years) was superior
to clinical benefit from renal-related morbidity (59  9%
at 10 years) (Fig, E). Using proportional hazard analysis,
the predictors of long-term clinical benefit were ipsilat-
eral kidney size (9 cm) (HR 0.24, 0.36 to 0.12,
P  .001), no immediate deterioration in function (HR
0.47, 0.01 to 0.88, P  .004) and a eGFR 30 mL/
min/1.73m2 (HR 0.44, 0.72 to 0.14, P  .02).
Neither control of diabetes (HR 1.2, 0.88 to 1.94, P 
.41) nor the administration of statins (HR 1.34, 0.86 to
2.14, P  .30) was shown to influence outcomes in the
Table IV. Outcomes








Deterioration 10% 7% .44No change 90% 93%
Immediate renal outcomes
Deterioration 8% 19%
.03No change 86% 69%Improved 5% 11%
Cured 1% 1%
Long Term Renal Outcomes
Increase in creatinine 21% 22% .86
Progression to hemodialysis 7% 15% .07
Death from renal cause 2% 3% .65solitary functioning kidney.
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Volume 49, Number 4 Davies et al 957Fig. A, Survival: Kaplan-Meier analysis of survival of the patients with a solitary kidney or a normal contralateral kidney. The
number at risk at each time interval is shownbeloweachpanel. Values aremean standard error of themean. Standard errors
exceeding 10% are not shown. B, Patency: Kaplan-Meier analysis of cumulative patency with a solitary kidney or a normal
contralateral kidney. The number at risk at each time interval is shown below each panel. Values are mean standard error
of themean. Standard errors exceeding 10% are not shown.C,Restenosis: Kaplan-Meier analysis of freedom from restenosis
of the patients with a solitary kidney or a normal contralateral kidney. The number at risk at each time interval is shownbelow
each panel. Values are mean  standard error of the mean. Standard errors exceeding 10% are not shown. D, Recurrent
symptoms: Kaplan-Meier analysis of freedom from renal-related morbidity (persistent increase in creatinine 20% of
baseline, progression to hemodialysis, death from renal-related causes) of the patients with a solitary kidney or a normal
contralateral kidney. The number at risk at each time interval is shown below each panel. Values are mean standard error
of the mean. Standard errors exceeding 10% are not shown. E, Retained clinical benefit from recurrent hypertension and
renal-related morbidity in the solitary kidney: Kaplan-Meier analysis of freedom from recurrent hypertension and renal-
related morbidity (increase in persistent creatinine20% of baseline, progression to hemodialysis, death from renal-related
causes) of the patients with a solitary kidney. The number at risk at each time interval is shown below each panel. Values are
mean standard error of the mean. Standard errors exceeding 10% are not shown.
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This series represents one of the largest reports on
treatment of ARAS in the solitary functioning kidney.
Intervention in patients with a solitary functioning kidney
and appropriate symptoms is a safe procedure and compares
favorably with those interventions performed for ARAS and
a normal contralateral kidney. Intervention did improve or
stabilize renal function in 82% of the patients presenting
with ARAS in a solitary kidney. Although overall survival in
these patients is much lower than if a normal contralateral
kidney were present, the recurrence of symptoms was
equivalent (59  10% and 73  7%) at 5 years supporting
the longer term clinical efficacy of interventions in these
patients. Clinical benefit appeared to be dictated by preop-
erative eGFR, renal size, and the occurrence of acute func-
tional injury after the procedure.
At the present time, there are no unique established
criteria for endovascular treatment of renal artery stenosis in
a solitary functioning kidney. One criterion suggested has
been kidney size, as it is reported that a pole-to-pole length
of less than 8 cm is a significant predictor that revascular-
ization will not help in improving renal function.15 This
was also taken into consideration in our patient selection
with a mean kidney size of 11 cm, but we did perform
procedures in kidneys with a minimum renal size of 7 cm
during the early part of the series. A second criterion often
employed is the anatomic location of the stenosis, as an
ostial localization has a more favorable outcome than a
peripheral lesion.16,17 A third criterion is the degree of
stenosis present. While it has been shown that stenosis less
than 60% have a 48% chance of progressing into significant
stenosis in 3 years.12 A stenosis greater than 75% becomes
an occlusion in 13 months in 39% of cases.18 A final
criterion is the state and rate of decline of the renal insuffi-
ciency. Hanson et al have clearly demonstrated that interven-
ing in a patient who is in the declining phase of renal insuffi-
ciency is far superior than intervening in the patient where the
deterioration is established and long standing.19-22
Renal artery stenosis is an independent predictor of
mortality. At 7 years, 73% of patients with renal artery
stenosis are dead.23 The 7-year mortality in this study for
patients with a solitary kidney was 66%, which is equivalent
to untreated disease and was significantly higher than those
patients with two kidneys (32% at 7 years). Similar to the
current study, immediate and long-term postprocedure
creatinine deterioration and dialysis-dependency have been
associated with increased mortality.1,2,24 We have also
shown that acute functional injury (ie, a rise in creatinine
0.5 mg/dL) also has a significant impact on survival.11
There was a significant incidence in acute functional injury
in the solitary kidney group that likely impacted the sur-
vival. Elevated creatinine has already been shown to affect
survival after therapy for renal artery stenosis despite ade-
quate revascularization.1,2,24 Intervention in the solitary
kidney did not appear to influence survival.
Technical success defined as 30% residual stenosis at
the end of the procedure has been reported to be between93-100% for endovascular interventions in the solitary kid-
ney. Cumulative patency rates in this series determined by
serial duplex scan imaging were 81  5% vs 87  6% at 5
years and 68% vs 83% at 10 years for normal and solitary
kidney groups. In a series of 15 patients by Sahin et al,25
primary patency rates were 100% for 6 months, 92.3% for
12 months, and 69.2% for 24 months. The secondary
patency rate at 24months was 100%. In another series of 16
patients by Cioni et al,26 cumulative primary patency rate
was 81% at 12 months and 75% at 24 months. We had a 0%
mortality rate and an all-cause morbidity rate of 12%, all of
which were minor. Other reports have shown mortality
rates ranging from 0% to 4% and all-cause morbidity rates
ranging from 27% to 43%.25-27 These data compared very
favorably to open surgery where perioperative mortality
was 6%, and major morbidity was 43%, including the need
for permanent (9%) and temporary (9%) dialysis.28 It thus
appears that intervention in the solitary kidney has a rela-
tively low mortality and morbidity compared to historical
data on endoluminal intervention and open surgery.
After simple angioplasty in all comers, improvement or
cure of BP has been reported as 66-100%, and improve-
ment or stabilization of the renal functions was reported as
38-100%.29-32 In contrast, after primary stent placement,
improvement or cure of BP was reported as 44-100% and
improvement or stabilization of the renal functions was
reported as 24-100%.17,26,33-37 While the immediate clin-
ical outcomes in patients with a normal contralateral kidney
demonstrated numbers in these ranges (hypertension 60%
and renal 92%) those with a solitary kidney were much less
likely for hypertension (20%) and equivalent for renal
(81%). Bush et al27 reported improvement in renal function
in 46% of patients, no change in 28%, and deterioration in
25% while Shannon et al38 reported 43%, 29%, and 29%,
respectively. In comparison, only 12% of patients treated in
this study demonstrated immediate clinical benefit of im-
proved or cured renal dysfunction and 69% showed no
change within 3 months of procedure. This data was equiv-
alent to the control group except we saw a greater propor-
tion of patients showing deterioration in renal function.
While the improvement rates were lower than previous
reports, a lower proportion of deterioration than in those
previous reports balanced this. Only 19% of patients
showed deterioration in their renal function with 3 months
of intervention lower than the reports by Bush (25%) and
Shannon (29%), however, twofold greater than our control
group. We did find that a preprocedure eGFR 30 mL/
min/1.73m2 was associated with immediate renal benefit
in those patients with a solitary kidney. Long-term clinical
benefit from renal-related morbidity was 59% at 5 years and
was predicted by ipsilateral kidney size (9 cm), no imme-
diate deterioration in renal function and a eGFR 30
mL/min/1.73m2. In contrast to these percutaneous re-
sults, Reilly et al28 reported the outcomes of open surgical
interventions in 35 patients and showed that 91% of pa-
tients had stable or improved renal function and that hy-
pertension was cured or improved in 85%. The current data
suggests that a quantification of residual function through
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 4 Davies et al 959both biochemical and functional assessments in the solitary
kidney will predict success and will allow better stratifica-
tion of indications for intervention.
CONCLUSION
Intervention in patients with a solitary functioning
kidney is a safe procedure and in the short term improves or
stabilizes renal function in 82% of patients. Clinical benefit
is dictated by preoperative eGFR, renal size, and the occur-
rence of acute functional injury after the procedure.
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